Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting
drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD).